安永吴晓颖：创新药回暖非短期炒作，三大"风向标"验证复苏成色

Core Insights - The Chinese biopharmaceutical industry is showing signs of recovery in 2025, with increased license-out transactions, a rebound in primary market financing, and the return of cornerstone investors in Hong Kong biotech IPOs, suggesting a shift from a prolonged downturn to a more normalized state [1][2][4] Group 1: Market Recovery and Trends - The market is transitioning from an "extreme compression" phase to a "relatively normal" state, indicating a quality recovery rather than a full-blown boom [2][4] - The overall pharmaceutical industry saw a 16.72% increase from early 2025 to November, outperforming the CSI 300 index by 1.68 percentage points, driven by breakthroughs in innovative drugs [2][3] - License-out transactions in the innovative drug sector reached $93.7 billion in the first three quarters of 2025, a 64% increase year-on-year, surpassing the total financing amount in the primary market for the first time [3][4] Group 2: Structural Changes and Investment Logic - The core driving forces behind the industry's progress are structural changes rather than short-term stimuli, with a focus on rational project selection and differentiation in product pipelines [2][5] - Investors are increasingly prioritizing clinical data certainty, product differentiation, and global commercialization potential over chasing trends [2][4] - The competitive edge of Chinese innovative drugs has significantly improved, leading to increased cross-border licensing collaborations and the emergence of new cross-border companies [4][5] Group 3: Challenges and Future Indicators - Despite positive trends, challenges such as global interest rate changes, geopolitical uncertainties, and ongoing pressures on domestic healthcare payments remain [4][5] - Key indicators for assessing the sustainability of the recovery include the continued occurrence of high-quality license-out transactions and the ability of Hong Kong to nurture companies with solid data and commercialization capabilities [5][12] Group 4: Global Integration and Market Dynamics - The integration of Chinese innovative drugs into the global pharmaceutical ecosystem is evident, with cross-border collaborations becoming crucial for value realization [11][12] - The return of overseas investors to Hong Kong biotech IPOs reflects a long-term rebuilding of confidence, contingent on companies having globally competitive product pipelines and clear clinical data timelines [11][12] - The differentiation in market dynamics necessitates careful selection of IPO venues based on pipeline stages, funding needs, and adaptability to market rules [12][13] Group 5: Strategic Considerations for Biotech Companies - For small and medium-sized biotech firms, balancing global R&D and commercialization with solidifying the domestic market is a critical challenge [13][14] - A phased globalization approach is recommended, where early R&D aligns with international standards while domestic commercialization focuses on core areas to validate product value [13][14] - The industry's evolution emphasizes quality, differentiation, and global capability, with the 2025 recovery seen as a return to normalcy after a period of structural advantage accumulation [14]